Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK104 in Advanced Solid Tumors (Ib/II, Single-Arm)
CTR20191326Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Jul 2019
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab in non-small cell lung cancer (NSCLC), melanoma, nasopharyngeal carcinoma (NPC), gastric cancer (GC), triple-negative breast cancer (TNBC), sponsored by Akeso, Inc.. Started Jul 2019; status: completed.
02
Drugs
cadonilimab
03
Conditions
non-small cell lung cancer (NSCLC)melanomanasopharyngeal carcinoma (NPC)gastric cancer (GC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on CTR20191326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191326.